サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1291544

非アルコール性脂肪肝炎（NASH）市場：薬剤タイプ、疾病原因、販売チャネル、エンドユーザー、地域　2023-2028年

Non-Alcoholic Steatohepatitis Market by Drug Type, Disease Cause, Sales Channel, End User, and Region 2023-2028
出版日: | 発行: IMARC | ページ情報: 英文 142 Pages | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
非アルコール性脂肪肝炎（NASH）市場：薬剤タイプ、疾病原因、販売チャネル、エンドユーザー、地域　2023-2028年
出版日: 2023年05月29日
発行: IMARC
ページ情報: 英文 142 Pages
納期: 2～3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

市場概要：

世界の非アルコール性脂肪肝炎（NASH）市場規模は、2022年に12億1,000万米ドルに達しました。今後、IMARC Groupは、2023年から2028年の間に27.70%の成長率（CAGR）を示し、2028年までに55億5,000万米ドルに達すると予測しています。NASHの有病率の上昇、早期診断と治療に関する意識の高まり、人工知能（AI）と機械学習（ML）技術の統合が、市場を牽引する重要な要因の一部となっています。

非アルコール性脂肪肝炎（NASH）は、インスリン抵抗性、過体重、メタボリックシンドロームによって引き起こされる進行性の非アルコール性脂肪性肝疾患（NAFLD）のことを指します。その症状は、疲労や脱力感、体重減少、黄疸、皮膚のかゆみ、クモ状静脈、肝臓の肥大、集中力の欠如、液体の蓄積、痛みや腫れなどの腹部不快感を伴う。身体検査、血液検査、肝生検、磁気共鳴画像法（MRI）、超音波検査、コンピュータ断層撮影（CT）検査など、複数の手法で診断されます。NASHの治療には、薬物療法、肝移植、定期的な運動や健康的な食事などの様々な生活習慣の改善が含まれます。これらの治療法は、肝脂肪の蓄積を抑え、肝機能を改善し、炎症を抑え、肝障害を最小限に抑えるのに役立ちます。また、患者さんのQOL（生活の質）を高め、長期的な予後を改善し、肥満や高血圧など他の健康問題をよりよく管理することができます。

非アルコール性脂肪肝炎（NASH）の市場動向：

遺伝、座りがちなライフスタイル、不健康な食習慣、肥満、2型糖尿病などによるNASHの有病率の上昇は、市場の成長を促す重要な要因の1つです。これに伴い、NASH治療は、症状の緩和、寿命の延長、早期死亡の防止、肝臓の健康増進、全身の健康増進を目的として患者に広く採用されており、ひいては市場成長の推進力となっています。さらに、医療費の削減、肝移植の必要性の排除、高血圧、心血管疾患（CVD）、がん、肝硬変、肝不全などの将来の合併症の予防のために、NASHの早期診断と治療に関する大衆の意識の高まりが、市場成長に弾みをつけています。さらに、MRIや過渡エラストグラフィ（TE）など、NASHのモニタリングや診断に非侵襲的な画像技術を活用することで、患者の快適性を高め、コンプライアンスを高め、合併症のリスクを低減し、臨床結果を改善することが、市場成長にプラスの影響を与えています。このほか、人工知能（AI）と機械学習（ML）の統合による個別化治療の開発、診断精度の向上、疾患進行の予測は、市場の成長に好影響を与えています。さらに、質の高い治療へのアクセスを提供し、先進的な治療薬の開発を支援するためのさまざまな政府イニシアチブの実施が、市場の成長を促進しています。その他の要因として、高齢者人口の増加、医療費の増加、大規模な研究開発活動、ヘルスケア産業の著しい成長、非侵襲的な治療オプションに対する需要の増加などが、市場の成長を促進すると予想されます。

本レポートで回答した主な質問

  • 世界の非アルコール性脂肪肝炎（NASH）市場はこれまでどのように推移し、今後数年間はどのように推移するのか？
  • 世界の非アルコール性脂肪肝炎（NASH）市場における市場促進要因、抑制要因、および機会は何か？
  • 各駆動要因、抑制要因、機会が世界の非アルコール性脂肪肝炎（NASH）市場に与える影響とは？
  • 主要な地域市場とは？
  • 最も魅力的な非アルコール性脂肪肝炎（NASH）市場を代表する国はどこか？
  • 薬剤タイプに基づく市場の内訳は？
  • 非アルコール性脂肪肝炎（NASH）市場において最も魅力的な薬剤タイプは何か？
  • 疾病原因に基づく市場の内訳は？
  • 非アルコール性脂肪肝炎（NASH）市場において最も魅力的な疾患原因は何か？
  • 販売チャネルに基づく市場の内訳は？
  • 非アルコール性脂肪肝炎（NASH）市場において最も魅力的な販売チャネルはどこか？
  • エンドユーザー別の市場内訳は？
  • 非アルコール性脂肪肝炎（NASH）市場において最も魅力的なエンドユーザーはどこか？
  • 世界の非アルコール性脂肪肝炎（NASH）市場の競争構造はどうなっているか？
  • 世界の非アルコール性脂肪肝炎（NASH）市場における主要プレイヤー/企業は？

目次

第1章 序文

第2章 調査範囲と調査手法

  • 調査目的
  • 利害関係者
  • データソース
    • 一次情報
    • 二次情報
  • 市場推定
    • ボトムアップアプローチ
    • トップダウンアプローチ
  • 予測手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

  • 概要
  • 主要産業動向

第5章 非アルコール性脂肪肝炎（NASH）の世界市場

  • 市場概要
  • 市場実績
  • COVID-19のインパクト
  • 市場予測

第6章 薬剤タイプ別市場内訳

  • ビタミンEとピオグリタゾン
    • 市場動向
    • 市場予測
  • オカリバ
    • 市場動向
    • 市場予測
  • エラフィブラノール
    • 市場動向
    • 市場予測
  • セロンセルティブ
    • 市場動向
    • 市場予測
  • セニクリビロク
    • 市場動向
    • 市場予測
  • その他
    • 市場動向
    • 市場予測

第7章 疾病原因別市場内訳

  • 高血圧症
    • 市場動向
    • 市場予測
  • 心臓病
    • 市場動向
    • 市場予測
  • 高脂血症
    • 市場動向
    • 市場予測
  • 2型糖尿病
    • 市場動向
    • 市場予測
  • 肥満症
    • 市場動向
    • 市場予測

第8章 販売チャネル別市場内訳

  • 病院薬局
    • 市場動向
    • 市場予測
  • オンラインプロバイダー
    • 市場動向
    • 市場予測
  • 小売薬局
    • 市場動向
    • 市場予測

第9章 エンドユーザー別市場内訳

  • 病院
    • 市場動向
    • 市場予測
  • 診療所
    • 市場動向
    • 市場予測
  • 在宅医療
    • 市場動向
    • 市場予測

第10章 地域別市場内訳

  • 北米
    • 米国
      • 市場動向
      • 市場予測
    • カナダ
      • 市場動向
      • 市場予測
  • アジア太平洋地域
    • 中国
      • 市場動向
      • 市場予測
    • 日本
      • 市場動向
      • 市場予測
    • インド
      • 市場動向
      • 市場予測
    • 韓国
      • 市場動向
      • 市場予測
    • オーストラリア
      • 市場動向
      • 市場予測
    • インドネシア
      • 市場動向
      • 市場予測
    • その他
      • 市場動向
      • 市場予測
  • 欧州
    • ドイツ
      • 市場動向
      • 市場予測
    • フランス
      • 市場動向
      • 市場予測
    • 英国
      • 市場動向
      • 市場予測
    • イタリア
      • 市場動向
      • 市場予測
    • スペイン
      • 市場動向
      • 市場予測
    • ロシア
      • 市場動向
      • 市場予測
    • その他
      • 市場動向
      • 市場予測
  • ラテンアメリカ
    • ブラジル
      • 市場動向
      • 市場予測
    • メキシコ
      • 市場動向
      • 市場予測
    • その他
      • 市場動向
      • 市場予測
  • 中東・アフリカ地域
    • 市場動向
    • 国別市場内訳
    • 市場展望

第11章 促進要因、抑制要因、および機会

  • 概要
  • 促進要因
  • 抑制要因
  • 機会

第12章 バリューチェーン分析

第13章 ポーターのファイブフォース分析

  • 概要
  • 買い手の交渉力
  • 供給企業の交渉力
  • 競合の度合い
  • 新規参入業者の脅威
  • 代替品の脅威

第14章 価格分析

第15章 競合情勢

  • 市場構造
  • 主要企業
  • 主要企業のプロファイル
    • Algernon Pharmaceuticals
    • Galmed Pharmaceuticals Ltd
    • Intercept Pharmaceuticals Inc.
    • Zydus Lifesciences Limited

本レポートに記載されている企業名は一部であり、全企業名は本レポートに記載されています。

図表

List of Figures

  • Figure 1: Global: Non-Alcoholic Steatohepatitis Market: Major Drivers and Challenges
  • Figure 2: Global: Non-Alcoholic Steatohepatitis Market: Sales Value (in Billion US$), 2017-2022
  • Figure 3: Global: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Billion US$), 2023-2028
  • Figure 4: Global: Non-Alcoholic Steatohepatitis Market: Breakup by Drug Type (in %), 2022
  • Figure 5: Global: Non-Alcoholic Steatohepatitis Market: Breakup by Disease Cause (in %), 2022
  • Figure 6: Global: Non-Alcoholic Steatohepatitis Market: Breakup by Sales Channel (in %), 2022
  • Figure 7: Global: Non-Alcoholic Steatohepatitis Market: Breakup by End User (in %), 2022
  • Figure 8: Global: Non-Alcoholic Steatohepatitis Market: Breakup by Region (in %), 2022
  • Figure 9: Global: Non-Alcoholic Steatohepatitis (Vitamin E and Pioglitazone) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 10: Global: Non-Alcoholic Steatohepatitis (Vitamin E and Pioglitazone) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 11: Global: Non-Alcoholic Steatohepatitis (Ocaliva) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 12: Global: Non-Alcoholic Steatohepatitis (Ocaliva) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 13: Global: Non-Alcoholic Steatohepatitis (Elafibranor) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 14: Global: Non-Alcoholic Steatohepatitis (Elafibranor) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 15: Global: Non-Alcoholic Steatohepatitis (Selonsertib) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 16: Global: Non-Alcoholic Steatohepatitis (Selonsertib) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 17: Global: Non-Alcoholic Steatohepatitis (Cenicriviroc) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 18: Global: Non-Alcoholic Steatohepatitis (Cenicriviroc) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 19: Global: Non-Alcoholic Steatohepatitis (Other Drug Types) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 20: Global: Non-Alcoholic Steatohepatitis (Other Drug Types) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 21: Global: Non-Alcoholic Steatohepatitis (Hypertension) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 22: Global: Non-Alcoholic Steatohepatitis (Hypertension) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 23: Global: Non-Alcoholic Steatohepatitis (Heart Disease) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 24: Global: Non-Alcoholic Steatohepatitis (Heart Disease) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 25: Global: Non-Alcoholic Steatohepatitis (High Blood Lipid) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 26: Global: Non-Alcoholic Steatohepatitis (High Blood Lipid) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 27: Global: Non-Alcoholic Steatohepatitis (Type 2 Diabetes) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 28: Global: Non-Alcoholic Steatohepatitis (Type 2 Diabetes) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 29: Global: Non-Alcoholic Steatohepatitis (Obesity) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 30: Global: Non-Alcoholic Steatohepatitis (Obesity) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 31: Global: Non-Alcoholic Steatohepatitis (Hospital Pharmacy) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 32: Global: Non-Alcoholic Steatohepatitis (Hospital Pharmacy) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 33: Global: Non-Alcoholic Steatohepatitis (Online Providers) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 34: Global: Non-Alcoholic Steatohepatitis (Online Providers) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 35: Global: Non-Alcoholic Steatohepatitis (Retail Pharmacy) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 36: Global: Non-Alcoholic Steatohepatitis (Retail Pharmacy) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 37: Global: Non-Alcoholic Steatohepatitis (Hospitals) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 38: Global: Non-Alcoholic Steatohepatitis (Hospitals) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 39: Global: Non-Alcoholic Steatohepatitis (Clinics) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 40: Global: Non-Alcoholic Steatohepatitis (Clinics) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 41: Global: Non-Alcoholic Steatohepatitis (Homecare Settings) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 42: Global: Non-Alcoholic Steatohepatitis (Homecare Settings) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 43: North America: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 44: North America: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 45: United States: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 46: United States: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 47: Canada: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 48: Canada: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 49: Asia-Pacific: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 50: Asia-Pacific: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 51: China: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 52: China: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 53: Japan: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 54: Japan: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 55: India: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 56: India: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 57: South Korea: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 58: South Korea: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 59: Australia: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 60: Australia: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 61: Indonesia: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 62: Indonesia: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 63: Others: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 64: Others: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 65: Europe: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 66: Europe: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 67: Germany: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 68: Germany: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 69: France: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 70: France: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 71: United Kingdom: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 72: United Kingdom: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 73: Italy: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 74: Italy: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 75: Spain: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 76: Spain: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 77: Russia: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 78: Russia: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 79: Others: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 80: Others: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 81: Latin America: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 82: Latin America: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 83: Brazil: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 84: Brazil: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 85: Mexico: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 86: Mexico: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 87: Others: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 88: Others: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 89: Middle East and Africa: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 90: Middle East and Africa: Non-Alcoholic Steatohepatitis Market: Breakup by Country (in %), 2022
  • Figure 91: Middle East and Africa: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 92: Global: Non-Alcoholic Steatohepatitis Industry: Drivers, Restraints, and Opportunities
  • Figure 93: Global: Non-Alcoholic Steatohepatitis Industry: Value Chain Analysis
  • Figure 94: Global: Non-Alcoholic Steatohepatitis Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Non-Alcoholic Steatohepatitis Market: Key Industry Highlights, 2022 & 2028
  • Table 2: Global: Non-Alcoholic Steatohepatitis Market Forecast: Breakup by Drug Type (in Million US$), 2023-2028
  • Table 3: Global: Non-Alcoholic Steatohepatitis Market Forecast: Breakup by Disease Cause (in Million US$), 2023-2028
  • Table 4: Global: Non-Alcoholic Steatohepatitis Market Forecast: Breakup by Sales Channel (in Million US$), 2023-2028
  • Table 5: Global: Non-Alcoholic Steatohepatitis Market Forecast: Breakup by End User (in Million US$), 2023-2028
  • Table 6: Global: Non-Alcoholic Steatohepatitis Market Forecast: Breakup by Region (in Million US$), 2023-2028
  • Table 7: Global: Non-Alcoholic Steatohepatitis Market: Competitive Structure
  • Table 8: Global: Non-Alcoholic Steatohepatitis Market: Key Players
目次
Product Code: SR112023A7397

Market Overview:

The global non-alcoholic steatohepatitis (NASH) market size reached US$ 1.21 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 5.55 Billion by 2028, exhibiting a growth rate (CAGR) of 27.70% during 2023-2028. The rising prevalence of NASH, increasing awareness regarding early diagnosis and treatments, and the integration of artificial intelligence (AI) and machine learning (ML) technologies represent some of the key factors driving the market.

Non-alcoholic steatohepatitis (NASH) refers to a progressive non-alcoholic fatty liver disease (NAFLD) caused by insulin resistance, overweight, and metabolic syndrome. Its symptoms involve fatigue and weakness, weight loss, jaundice, itchy skin, spider veins, enlarged liver, lack of concentration, fluid accumulation, and abdominal discomfort, such as pain and swelling. It is diagnosed through multiple techniques, such as physical examination, blood test, liver biopsy, magnetic resonance imaging (MRI), ultrasound, and computed tomography (CT) scan. NASH treatment includes medication, liver transplant, and various lifestyle modifications, such as regular exercise, and healthy diets. These treatment methods aid in reducing liver fat accumulation, improving liver function, reducing inflammation, and minimizing liver damage. They also enhance patients' quality of life, improve long-term outcomes, and allow better management of other health problems, such as obesity and high blood pressure.

Non-Alcoholic Steatohepatitis (NASH) Market Trends:

The rising prevalence of NASH due to genetics, sedentary lifestyle, unhealthy eating habits, obesity, and type 2 diabetes is one of the key factors driving the market growth. In line with this, NASH treatments are widely adopted by patients to alleviate symptoms, increase lifespan, prevent premature death, improve liver health, and promote overall well-being, which in turn is providing a thrust to the market growth. Furthermore, the increasing awareness among the masses regarding early diagnosis and treatment of NASH to reduce healthcare expenses, eliminate the need for liver transplants, and prevent future complications, such as high blood pressure, cardiovascular diseases (CVDs), cancer, cirrhosis, and liver failure is providing an impetus to the market growth. Additionally, the utilization of non-invasive imaging techniques to monitor and diagnose NASH, such as MRI and transient elastography (TE), which, in turn, enhances patients' comfort, increases compliance, reduces the risk of complications, and improves clinical outcomes, is positively influencing the market growth. Besides this, the integration of artificial intelligence (AI) and machine learning (ML) to develop personalized treatments, improve diagnosis accuracy, and predict disease progression is favoring the market growth. Moreover, the implementation of various government initiatives to provide access to high-quality treatment and support the development of advanced therapeutics is propelling the market growth. Other factors, including the rising geriatric population, increasing healthcare expenditure, extensive research and development (R&D) activities, significant growth in the healthcare industry, and the increasing demand for non-invasive treatment options, are anticipated to drive the market growth. 

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the global non-alcoholic steatohepatitis (NASH) market, along with forecasts at the global, regional, and country levels from 2023-2028. Our report has categorized the market based on drug type, disease cause, sales channel, and end user.

Drug Type Insights:

  • Vitamin E and Pioglitazone
  • Ocaliva
  • Elafibranor
  • Selonsertib
  • Cenicriviroc
  • Others

The report has provided a detailed breakup and analysis of the non-alcoholic steatohepatitis (NASH) market based on the drug type. This includes Vitamin E and Pioglitazone, Ocaliva, Elafibranor, Selonsertib, Cenicriviroc, and others. According to the report, vitamin E and pioglitazone represented the largest segment.

Disease Cause Insights:

  • Hypertension
  • Heart Disease
  • High Blood Lipid
  • Type 2 Diabetes
  • Obesity

A detailed breakup and analysis of the non-alcoholic steatohepatitis (NASH) market based on the disease cause has also been provided in the report. This includes hypertension, heart disease, high blood lipid, type 2 diabetes, and obesity. According to the report, obesity accounted for the largest market share.

Sales Channel Insights:

  • Hospital Pharmacy
  • Online Providers
  • Retail Pharmacy

A detailed breakup and analysis of the non-alcoholic steatohepatitis (NASH) market based on the sales channel has also been provided in the report. This includes hospital pharmacy, online providers, and retail pharmacy. According to the report, retail pharmacy accounted for the largest market share.

End User Insights:

  • Hospitals
  • Clinics
  • Homecare Settings

A detailed breakup and analysis of the non-alcoholic steatohepatitis (NASH) market based on the end user has also been provided in the report. This includes hospitals, clinics, and homecare settings. According to the report, clinics accounted for the largest market share.

Regional Insights:

  • North America
    • United States
    • Canada
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America was the largest market for non-alcoholic steatohepatitis (NASH). Some of the factors driving the North America non-alcoholic steatohepatitis (NASH) market included the rising prevalence of NASH, increasing government initiatives, and rapid technological advancements.

Competitive Landscape:

The report has also provided a comprehensive analysis of the competitive landscape in the global non-alcoholic steatohepatitis (NASH) market. Competitive analysis such as market structure, market share by key players, player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided. Some of the companies covered include Algernon Pharmaceuticals, Galmed Pharmaceuticals Ltd, Intercept Pharmaceuticals Inc., Zydus Lifesciences Limited, etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

Key Questions Answered in This Report:

  • How has the global non-alcoholic steatohepatitis (NASH) market performed so far, and how will it perform in the coming years?
  • What are the drivers, restraints, and opportunities in the global non-alcoholic steatohepatitis (NASH) market?
  • What is the impact of each driver, restraint, and opportunity on the global non-alcoholic steatohepatitis (NASH) market?
  • What are the key regional markets?
  • Which countries represent the most attractive non-alcoholic steatohepatitis (NASH) market?
  • What is the breakup of the market based on the drug type?
  • Which is the most attractive drug type in the non-alcoholic steatohepatitis (NASH) market?
  • What is the breakup of the market based on the disease cause?
  • Which is the most attractive disease cause in the non-alcoholic steatohepatitis (NASH) market?
  • What is the breakup of the market based on sales channel?
  • Which is the most attractive sales channel in the non-alcoholic steatohepatitis (NASH) market?
  • What is the breakup of the market based on end user?
  • Which is the most attractive end user in the non-alcoholic steatohepatitis (NASH) market?
  • What is the competitive structure of the global non-alcoholic steatohepatitis (NASH) market?
  • Who are the key players/companies in the global non-alcoholic steatohepatitis (NASH) market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Non-Alcoholic Steatohepatitis (NASH) Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Drug Type

  • 6.1 Vitamin E and Pioglitazone
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Ocaliva
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Elafibranor
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Selonsertib
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 Cenicriviroc
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast
  • 6.6 Others
    • 6.6.1 Market Trends
    • 6.6.2 Market Forecast

7 Market Breakup by Disease Cause

  • 7.1 Hypertension
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Heart Disease
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 High Blood Lipid
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Type 2 Diabetes
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5 Obesity
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast

8 Market Breakup by Sales Channel

  • 8.1 Hospital Pharmacy
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Online Providers
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Retail Pharmacy
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast

9 Market Breakup by End User

  • 9.1 Hospitals
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Clinics
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 Homecare Settings
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast

10 Market Breakup by Region

  • 10.1 North America
    • 10.1.1 United States
      • 10.1.1.1 Market Trends
      • 10.1.1.2 Market Forecast
    • 10.1.2 Canada
      • 10.1.2.1 Market Trends
      • 10.1.2.2 Market Forecast
  • 10.2 Asia-Pacific
    • 10.2.1 China
      • 10.2.1.1 Market Trends
      • 10.2.1.2 Market Forecast
    • 10.2.2 Japan
      • 10.2.2.1 Market Trends
      • 10.2.2.2 Market Forecast
    • 10.2.3 India
      • 10.2.3.1 Market Trends
      • 10.2.3.2 Market Forecast
    • 10.2.4 South Korea
      • 10.2.4.1 Market Trends
      • 10.2.4.2 Market Forecast
    • 10.2.5 Australia
      • 10.2.5.1 Market Trends
      • 10.2.5.2 Market Forecast
    • 10.2.6 Indonesia
      • 10.2.6.1 Market Trends
      • 10.2.6.2 Market Forecast
    • 10.2.7 Others
      • 10.2.7.1 Market Trends
      • 10.2.7.2 Market Forecast
  • 10.3 Europe
    • 10.3.1 Germany
      • 10.3.1.1 Market Trends
      • 10.3.1.2 Market Forecast
    • 10.3.2 France
      • 10.3.2.1 Market Trends
      • 10.3.2.2 Market Forecast
    • 10.3.3 United Kingdom
      • 10.3.3.1 Market Trends
      • 10.3.3.2 Market Forecast
    • 10.3.4 Italy
      • 10.3.4.1 Market Trends
      • 10.3.4.2 Market Forecast
    • 10.3.5 Spain
      • 10.3.5.1 Market Trends
      • 10.3.5.2 Market Forecast
    • 10.3.6 Russia
      • 10.3.6.1 Market Trends
      • 10.3.6.2 Market Forecast
    • 10.3.7 Others
      • 10.3.7.1 Market Trends
      • 10.3.7.2 Market Forecast
  • 10.4 Latin America
    • 10.4.1 Brazil
      • 10.4.1.1 Market Trends
      • 10.4.1.2 Market Forecast
    • 10.4.2 Mexico
      • 10.4.2.1 Market Trends
      • 10.4.2.2 Market Forecast
    • 10.4.3 Others
      • 10.4.3.1 Market Trends
      • 10.4.3.2 Market Forecast
  • 10.5 Middle East and Africa
    • 10.5.1 Market Trends
    • 10.5.2 Market Breakup by Country
    • 10.5.3 Market Forecast

11 Drivers, Restraints, and Opportunities

  • 11.1 Overview
  • 11.2 Drivers
  • 11.3 Restraints
  • 11.4 Opportunities

12 Value Chain Analysis

13 Porters Five Forces Analysis

  • 13.1 Overview
  • 13.2 Bargaining Power of Buyers
  • 13.3 Bargaining Power of Suppliers
  • 13.4 Degree of Competition
  • 13.5 Threat of New Entrants
  • 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

  • 15.1 Market Structure
  • 15.2 Key Players
  • 15.3 Profiles of Key Players
    • 15.3.1 Algernon Pharmaceuticals
      • 15.3.1.1 Company Overview
      • 15.3.1.2 Product Portfolio
    • 15.3.2 Galmed Pharmaceuticals Ltd
      • 15.3.2.1 Company Overview
      • 15.3.2.2 Product Portfolio
      • 15.3.2.3 Financials
    • 15.3.3 Intercept Pharmaceuticals Inc.
      • 15.3.3.1 Company Overview
      • 15.3.3.2 Product Portfolio
      • 15.3.3.3 Financials
      • 15.3.3.4 SWOT Analysis
    • 15.3.4 Zydus Lifesciences Limited
      • 15.3.4.1 Company Overview
      • 15.3.4.2 Product Portfolio
      • 15.3.4.3 Financials
      • 15.3.4.4 SWOT Analysis

Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.